Cost-effectiveness of treatment sequences following first-line rituximab in relapsing-remitting multiple sclerosis: a Norwegian microsimulation study

Frontiers in Neurology

Apr 13

Written By Matthijs Versteegh

multiple sclerosis

Matthijs Versteegh

Antiarrhythmic drugs versus catheter ablation as rhythm control for atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials

Cost–Utility Analysis of Treatment Sequences for Moderate-to-Severe Crohn’s Disease